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Abstract
Background: Although there has been growing research on the burden of treatment, the current state of evidence
on measuring this concept is unknown. This scoping review aimed to provide an overview of the current state of
knowledge as well as clear recommendations for future research, within the context of chronic disease.
Methods: Four health-based databases, Scopus, CINAHL, Medline, and PsychInfo, were comprehensively searched
for peer-reviewed articles published between the periods of 2000–2016. Titles and abstracts were independently
read by two authors. All discrepancies between the authors were resolved by a third author. Data was extracted
using a standardized proforma and a comparison analysis was used in order to explore the key treatment burden
measures and categorize them into three groups.
Results: Database searching identified 1458 potential papers. After removal of duplications, and irrelevant articles by
title, 1102 abstracts remained. An additional 22 papers were added via snowball searching. In the end, 101 full papers
were included in the review. A large number of the studies involved quantitative measures and conceptualizations of
treatment burden (n = 64; 63.4%), and were conducted in North America (n = 49; 48.5%). There was significant
variation in how the treatment burden experienced by those with chronic disease was operationalized and measured.
Conclusion: Despite significant work, there is still much ground to cover to comprehensively measure treatment
burden for chronic disease. Greater qualitative focus, more research with cultural and minority populations, a larger
emphasis on longitudinal studies and the consideration of the potential effects of “identity” on treatment burden,
should be considered.
Keywords: Burden of treatment, Burden of medication, Treatment experience, Time burden, Workload burden, Cost of
illness, Chronic disease
Background
Globally, chronic diseases, such as diabetes, cancer and
asthma, are now in epidemic proportions [1]. With their in-
creasing prevalence, the focus for health professionals has
shifted from treating acute illness to helping their patients
manage the ‘work’ of living with such conditions [2, 3]. The
job of health professionals has been complicated by the fact
that chronic disease rarely occurs in isolation, with many
people experiencing two or more diseases concurrently,
something known as multimorbidity [4]. For patients, there
is not only the complexity of dealing with one chronic con-
dition, but the work of trying to live ‘normal’ lives in the
face of multimorbidity, which can be overwhelming. This
further adds to the ‘work’ that patients must do to manage
and live with such health conditions and the psychological
distress they experience as a result.
Lately, the work that patients need to do to manage and
treat chronic disease has been referred to as treatment
burden [5]. Treatment burden represents the active work
patients need to do including, learning about treatments
and their consequences, completing administrative tasks,
such as paper work, adhering to complex treatment regi-
mens, managing medications, changing lifestyle behaviours,
visiting multiple health professionals, and undertaking
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medical and other laboratory tests, etc. [6–8]. Treatment
burden is concerned with the negative experiences resulting
from the process of undertaking treatment [8]. The burden
of treatment can be dependent on the type of treatment a
person is undergoing. For example, chemotherapy to
destroy cancer cells or dialysis treatment for kidney disease
is much more invasive and burdensome compared to medi-
cation used to manage high blood pressure.
Sav et al. [8] reviewed research on treatment burden pub-
lished between 2000 and 2011 and suggested that a number
of factors can contribute to treatment burden for chronic
disease, including age and gender, illness duration or sever-
ity, treatment characteristics including the number and
dose of medications, and family circumstances such as level
of support. Sav et al. [8] further drew attention to the
dynamic nature of treatment burden suggesting that a per-
son’s overall perception of burden can change throughout
the course of their illness, depending on its severity and im-
pact. Tran et al. [9] in their existing taxonomy of treatment
burden, indicated that healthcare which imposes a burden
on patient’s include: management of medications, organis-
ing and performing non-pharmacological treatment,
lifestyle changes, condition and treatment follow-up, orga-
nising formal caregiver care, paperwork tasks, and earning
and developing an understanding of the illness and treat-
ment [6]. More recently, Demain et al. [10] discussed the
sociological aspect of treatment burden, suggesting that bur-
den is not only brought about by the workload associated
with a treatment regimen, but also the impact of that work-
load on everyday activities and a patient’s identity. For ex-
ample, elderly adults may be more likely, compared to
young adults, to accept treatment burden as a necessary evil
brought on by old age and living with multimorbidity. Fi-
nally, treatment burden is different from other related terms,
such as symptom burden, where the latter is focused on liv-
ing with the burden that the disease imposes, e.g. burden on
paid employment, and not on the need to treat the disease
in order to change its course or ameliorate its’ effects, which
is the focus of treatment burden [8]. Demain et al’s [10]
Tran et al’ [9] Sav et al’s [8, 11] research in the area of treat-
ment burden will be used as the conceptual framework to
guide data collection and analysis in this manuscript (see
Fig. 1). The framework, shows several antecedents, which
lead to burden, the major dimensions and consequences,
Fig. 1 Conceptual framework for the study
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operating in a cyclic nature (e.g., some consequences be-
come antecedents and vice versa). Of particular interest, the
conceptual framework shows the five key dimensions of
treatment burden, including, financial, medication, adminis-
trative, lifestyle, healthcare and time/travel.
Although treatment burden has gained popular research
momentum in the past decade, particularly since May et
al.’s seminal work in 2009 on “minimally disruptive medi-
cine”, debate continues around the best way to measure
and understand the level of treatment burden among pa-
tients. The absence of a universally accepted holistic
measure makes it difficult for researchers and health pro-
fessionals to understand levels of treatment burden among
patients, and hinders efforts to introduce effective inter-
ventions that reduce the level of burden experienced by
patients. Sav et al.’s [7] review found that treatment bur-
den has generally been measured as one dimension, e.g.
medication use, within a multidimensional instrument de-
signed to assess health-related quality of life or treatment
satisfaction. Sav et al. [8] argued that these measures had
wide variation in terms of the dimensions of treatment
burden and the way this concept was defined. Although
significant work has been conducted on treatment burden
since 2011, the current state of evidence on measuring
treatment burden is unknown. Yet, such knowledge is es-
sential in order to move forward and agree on the best
way to measure treatment burden in different populations
and with various or multiple chronic conditions.
In this paper we report results of a scoping review of the
literature on measuring treatment burden for chronic disease.
Our overarching objective is to provide an overview of the
current state of knowledge on how treatment burden for
chronic disease has been measured and conceptualized. It is
worth noting that our aim is not to conduct an assessment
of the quality of the selected literature (which is the aim of a
systematic review), nor to critique the statistical assessment
of treatment burden questionnaires. Rather, there was a need
to ‘scope’ the large but fragmented body of literature on how
a patient’s level of treatment burden, for a variety of chronic
conditions, has been measured. Our secondary aims are: (i)
to advance our conceptualization of the measurement of
treatment burden; (ii) understand the methodological issues
in developing treatment burden measurements; (iii) offer
clear recommendations for future research in this sphere to
develop our understanding of this concept.
Methods
A scoping review is a "form of knowledge synthesis that ad-
dresses an exploratory research question aimed at mapping
key concepts, types of evidence, and gaps in research related
to a defined area or field by systematically searching, select-
ing and synthesizing existing knowledge" [12], p. 1284. Scop-
ing reviews can be helpful in exploring research gaps,
setting research agendas and providing recommendations
for policy makers [13]. Although the quality of papers are
not assessed, scoping reviews explore a diverse range of
papers and provide a considerable summary of the relevant
literature [14–16]. Our scoping review was guided by five
of the six steps outlined by Arksey and O’Malley [14]. As a
widely cited and accepted way of conducting a scoping
review, this framework provided an opportunity to guide
the data collection and analysis in this study. The main
stages included:
(i) Classifying the research question. The key research
questions of this scoping review included (a) how
was treatment burden measured? (b) what is the
best way to measure this construct?
(ii)Finding the relevant studies/search strategy. The
authors identified the main concepts of the topic,
the burden of treatment in chronic health
conditions, and collated a list of relevant keywords.
The search strategy was refined by an initial search
of the literature to identify key MESH terms relating
to this topic. Four health-based databases, Scopus,
CINAHL, Medline and PsychInfo, were searched
using Boolean Operators for the following terms:
“treatment burden” OR “burden of treatment” OR
“medication burden” OR “burden of medication” OR
“treatment experience” OR “time burden” OR
“workload burden” OR “cost of illness” AND
“chronic disease”. Snowball searching, including
pursuing references of references and citations
searching, was also used.
(iii)Choosing the studies based on inclusion/exclusion
criteria. Inclusion and exclusion criteria were
developed by the authors during several meetings
and are described in Fig. 2 and guided by the
conceptual framework developed for this study
(Fig. 1). For example, to be included in the review,
papers needed to measure or focus on specific
dimensions of treatment burden, developed in the
conceptual framework (e.g. financial, medication,
administrative, lifestyle, healthcare and time/travel).
Peer-reviewed journal papers were included if they
were: published between the period of 2000–2016,
written in English, involved human participants and
described a measure for burden of treatment, e.g.
including single measurements, measuring and/or
incorporating one or two dimensions of burden of
treatment. Quantitative, qualitative and mixed-
method studies were included in order to consider
different aspects of measuring treatment burden.
Papers were excluded if they did not fit into the
conceptual framework of the study, focused on a
communicable chronic condition, for example
human immunodeficiency virus infection and
acquired immune deficiency syndrome (HIV/AIDS)
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or substance abuse. Papers talking about carer
burden, in addition to patient burden of treatment,
were also included.
(iv)Titles and abstracts were independently read by two
authors (AS & SM) using the inclusion criteria.
After applying the eligibility criteria, all remaining
papers were evenly allocated between three
authors (AS, NS and SM) and categorized into
included, excluded or unsure. Full-text of all
unsure papers was read by another author (AS,
NS or SM). In case of any disagreement, the
matter was resolved through in-depth discussion
between the authors. Charting the data. Data was
extracted using a standardized proforma, which
collected data on: year of publication, authors,
country, data collection, participant number and
chronic disease. The papers were divided between
three authors and the extracted data from all the
papers (particularly the treatment burden
categorization), were cross-checked in order to
reduce any possible individual bias [17].
Disagreements regarding the treatment burden
categories and data extractions were resolved by
discussions and brainstorming among two
authors, and then by involving a third author if
required [17].
(v)Collating, summarizing, and reporting the findings.
For all included papers, the instruments, and the key
dimensions of treatment burden, or both, were
described and compared. A comparison analysis was
used in order to explore the key treatment burden
measures and categorize the papers into three
groups (with the aid of the conceptual framework),
depending on the level of treatment burden
measured. The three groups were:
 Direct measures (Group 1): The paper clearly states
that it measures and/or explores treatment burden.
This category includes a more holistic approach to
treatment burden and measures all or most of the
dimensions in the conceptual framework developed
for this study
 Inferred measures (Group 2): The paper stated that
it measured treatment burden, however, it included
only one or two dimensions (which are included in
the conceptual framework), such as financial
burden, burden of time/travel. If the paper did not
contain the phrase ‘treatment burden’ or ‘burden of
treatment,’ then it was categorized into Group 3.
 Indirect measures (Group 3): No reference
specifically to treatment burden in the text or
‘burden of treatment.’ However, there is some
incorporated measure for one or two dimensions
of treatment burden, as per the conceptual
framework. Because treatment burden is still in
the developmental stage of operationalization, we
believed that the scoping review would have been
incomplete without its inclusion. Although these
papers do not specifically refer to the concept of
treatment burden they measure one or two of the
commonly accepted dimensions of the concept.
Furthermore, this was in line with the aim of a
scoping review, which aims to draw upon a
diverse range of papers and provide a
considerable summary of the relevant, available
literature.
Fig. 2 Framework of study categorization
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A summary of the data analysis framework used is
provided in Fig. 2.
Results
Database searching identified 1458 potential papers. After
removal of duplications, and irrelevant papers by title,
1102 abstracts remained. After applying the eligibility cri-
teria, 121 papers remained for further investigation. An
additional 22 papers were added via snowball searching.
After screening was completed 101, full papers were in-
cluded in the review. A flow chart describing the screen-
ing process is shown in Fig. 3. Included studies were
published between the years 2000–2016; a quarter of
the papers were published in 2015 (n = 26; 25.5%). The
majority of the studies involved quantitative measures
of treatment burden (n = 64; 63.4%). Twenty-eight
studies (27.7%) were qualitative, and nine (8.9%) were
mixed methods (see Table 1). One of these studies [18]
involved mathematical modelling to identify how treat-
ment burden influences treatment decisions.
From the 101 studies, a large majority were from North-
ern America (n = 49; 48.5%). There were 34 papers
(33.6%) from Europe (16, 15.8%, from the UK) and 10 pa-
pers (10%) from the Asia-Pacific. Four studies involved
participants from more than one country [9, 19–21].
Other sites included: Israel, Turkey, South Africa and
Jordan (please refer to Table 1).
The smallest sample size involved six adults in Baylor
et al.’s [22] phenomenological study, with the largest in-
volving a dataset of 1,424,378 people in Scotland [23].
Twenty-eight studies involved less than 50 participants,
23 of which used a qualitative study design. A total of
six studies involved more than 10,000 participants. Five
papers did not specifically state the age range of partici-
pants, while 61 papers 60.4%) focused on adults (18 to
Fig. 3 Overview of literature search and inclusion
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60 years of age), 12 (11.9%) on adults over the age of 60,
7 (6.9%) on children and adolescents, 6 (5.9%) on par-
ents and 10 (9.9%) on children and parents.
A range of chronic conditions were included, the majority
of which were grouped into one of the following
therapeutic areas: cancer, cardiovascular disease, diabetes,
psychological, respiratory, dermatological, or other, for ex-
ample, chronic kidney disease, coeliac disease, transplant,
primary ciliary dyskinesia and intensive care unit. The ma-
jority of studies focused on people with multimorbidities
(n = 24), followed by cancer (n = 18), respiratory conditions
(n = 17), diabetes (n = 13), psychological (n = 7), cardiovas-
cular (n = 5), dermatological (n = 2). Fifteen studies focused
on other chronic health conditions. The majority of studies
involving children (and/or parents) were for respiratory
conditions, e.g. cystic fibrosis. In accordance with the data
extraction strategy, papers were grouped into three categor-
ies and analyzed using this grouping system.
Group 1 - direct measures
There were a total of sixteen papers in this group. All
papers focused solely on understanding the burden of treat-
ment among adults, with chronic health conditions, with
Table 1 Study Characteristics
Characteristic No. of
studies
Geographical Region Northern America 49
Europe 18
United Kingdom 16
Asia-Pacific 10
Othera 4
Multi-siteb 4
Study Design Quantitative 64
Qualitative 28
Mixed Methods 9
Tool Development or Validationc 20
Sample size <50 28
50–100 11
100–500 32
500–1000 9
1000–10,000 15
>10,000 6
Study Participantsd Children & Adolescents 7
Parents 6
Adults (>18 years) 61
Adults (>60 years) 12
Children & Adults 10
Groupingse Group 1 16
Group 2 50
Group 3 35
Therapeutic Area Cancer/Tumour 18
Cardiovascular 5
Diabetes 13
Psychological 7
Respiratory 17
Dermatological 2
Otherf 15
Co-morbidities or various 24
Treatment Burdeng Medication 64
Time/Travel 32
Financial 22
Healthcare Access 21
Other: Lifestyle 16
Other: treatment preferences/decision/ 6
Other: Interpersonal challenges 3
Other: carer burden 3
Table 1 Study Characteristics (Continued)
Measuresh Semi-structured questions 31
Survey questions 24
Prescription burden 15
Disease specific tooli 28
aIsrael, Turkey, South Africa and Jordan;
bInvolving more than one country;
cOf all studies (counted twice)
dn = 5 did not specify population, ‘children and adults’ accounted for studies
involving children and their parents;
eRefer to Fig. 2 for more details about grouping
fIncludes: chronic/end-stage kidney disease, liver transplant, spasmodic
dysphonia, proliferative lupus nephritis, intensive care, gastroesophageal reflux
disease, primary ciliary dyskinesia, coeliac disease, systemic lupus
erythematosus, percutaneous endoscopic gastrostomy;
gSome papers included more than one dimension of treatment burden (will
not add to 101). Other aspects of treatment burden were identified, e.g.
dietary restrictions (lifestyle), the influence of treatment burden on treatment
preferences (treatment preferences/decisions), responses from others
(interpersonal challenges), and impact on carers (carer burden)
hOut of 98 papers – three studies did not use specific measures e.g. economic
evaluation, videographic analysis, normalization process theory on previous
interview data
iIncluded: versions of Cystic Fibrosis Questionnaire Revised (CFQ-R; n = 7);
Childhood Illness Attitude Scales (CIAS), versions of Quality of Life
Bronchiectasis (QOL-B) (n = 3 each); Burden of Insulin Treatment, Treatment
Related Impact Measure-Diabetes (Trim-D), Retinopathy Treatment Satisfaction
Questionnaire (RetTSQ), Survey of the Adolescent Treatment Experience (SATE),
Willingness to Accept Life-Saving Treatment (WALT), Elderly Diabetes Burden
Scale (n = 2 each); Patient Benefit Index - standard version for chronic skin
diseases (PBI-S), Diabetes Medication Satisfaction (DiabMedSat), Functional
Assessment of Chronic Illness Therapy-Treatment Satisfaction-Bone Treatment
Convenience and Satisfaction Questionnaire (FACIT-TS-BTCSQ), Medication
Cost Reduction Strategies (MCRS), Revised Illness Perception Questionnaire
(IPQR), Treatment Burden Index (TBI), Side effect rating scale, Dermatology Life
Quality Index (DLQI), GERD Treatment scale, Quality of Life in patients with
primary ciliary dyskinesia (QOL–PCD), Insulin Treatment Experience
Questionnaire (ITEQ), Markov model of diabetes outcomes (n = 1 each)
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the exception of Sav et al. [24], which explored the meaning
of treatment burden among stakeholders and key non-
government health organizations. Nine papers were qualita-
tive based [2, 11, 21, 24–29], five were quantitative [6, 9,
30–32], and two were mixed-methods studies [33, 34].
Two of the qualitative based papers used Normalization
Process Theory (NPT), which aims to explain how the
work of engaging in some ensemble of activities is accom-
plished through the operation of four mechanisms: coher-
ence, cognitive participation, collective action, and
reflexive monitoring, to interpret and categorize their data
analysis [2, 27]. Eton et al. [25] utilized this theory to in-
form interview questions in their study. Gallacher et al’s
[2] paper was based on secondary data (originally under-
taken to explore chronic heart failure), and the authors ex-
tracted information pertaining to treatment burden. Other
methods of data analysis included content analysis, the-
matic analysis, framework analysis, and Karamanidou et
al. [28] utilized Interpretive Phenomenological Analysis
(IPA). A review of the qualitative papers indicates that the
interview probe questions covered the following key di-
mensions of treatment burden in the literature: medica-
tion difficulties and/or experience, cost of treatment,
relationships with health professionals, understanding of
treatment and associated information needs, challenges/
barriers to treatment and/or self-management, lifestyle re-
strictions, family relationships, treatment adherence and
satisfaction. However, with the exception of Gallacher et
al. [1], Karamanidou et al. [28], Tran et al’s [21] paper, and
Eton et al’s [25, 26] papers, there was limited information
about the interview process and the specific questions
asked about treatment burden. Nevertheless, sample inter-
view questions in some of these papers included: ‘where
participants went for information regarding their illness,’
‘how treatment restricted their daily activities,’ ‘what par-
ticipants felt was the most difficult aspect to manage with
their treatment and illness,’ ‘whether participants believed
that it was important to follow their treatment regimen,’
and ‘whether participant’s felt that they knew enough
about their treatments.’ Eton et al’s (2012) paper on build-
ing a measurement framework of treatment burden in
complex patients with a range of chronic conditions was
the most comprehensive in terms of detailing the ques-
tions covered in the interviews. The authors included an
interview schedule in their paper, which consisted of 11
questions informed by previous studies of treatment im-
pact/satisfaction [35] and NPT. The authors used the
framework they developed in this study for their subse-
quent studies in 2015 and 2016, the latter being a quanti-
tative validation of a 9 factor, 48-item treatment burden
measure: the Patient Experience with Treatment and Self-
management (PETS).
In contrast to the qualitative papers, those utilizing a
quantitative design generally contained more descriptive
information about how treatment burden was measured.
For example, in 2006, Nordyke et al. [31] conducted a
study to validate a Patient Satisfaction Questionnaire for
Anemia Treatment (PSQ-An) in cancer patients. Although
their study was primarily concerned with treatment satis-
faction rather than burden, the latter was nevertheless
measured via a 10-item scale. However, there was limited
insight provided into how the treatment burden dimen-
sion of the PSQ-An was developed or the specific concep-
tual framework that was used. In another paper, focused
on cancer patients, Henry et al. [32] investigated the side
effects of chemotherapy or radiotherapy treatment; limited
information was provided about how this was measured
beyond referring to the 13-item Functional Assessment of
Chronic Illness Therapy (FACIT) Fatigue Scale (version
4). Bohlen et al. [33] examined (by video-graphic data)
whether people with type 2 diabetes and their clinicians
discussed treatment burden, the characteristics of their
discussions, and their attempts to address this burden
during visits. Based on previous research, the authors
identified four dimensions of treatment burden: access,
administration, effects, and monitoring. Also in 2012,
Tran et al. developed the Treatment Burden Question-
naire (TBQ) in France, which consisted of seven items
(two of which had four sub-items) in the French language.
Later, Tran et al. [21] adapted the TBQ amongst an Eng-
lish speaking sample using an internet platform. The TBQ
in this paper assessed the following dimensions: (1) taking
medication, (2) self-surveillance, laboratory tests, doctor
visits, need for organization and administrative tasks, (3)
following advice on diet and physical exercise, and (4) so-
cial impact of the treatment. The PETS measure, validated
by Eton et al. [30] included the following dimensions:
medication information, medications, medical appoint-
ments, monitoring health, interpersonal challenges,
medical expenses, difficulty with healthcare services, role
activity limitations, and physical/mental exhaustion.
Group 2 - inferred measures
A total of 50 papers were identified in Group 2. Despite
suggesting that they measured treatment burden, the pa-
pers in this group only included one or two established di-
mensions of treatment burden, e.g. financial costs, burden
of time. The majority of Group 2 papers were quantitative
studies (36 in total) [18, 19, 23, 36–68]. There were also
nine qualitative papers [22, 69–76], and five mixed-method
studies [20, 77–80].
There were wide variations within these papers with re-
spect to their level of focus on treatment burden. Some pa-
pers suggested a focus on treatment burden by their study
title, yet upon further inspection only included one or two
commonly accepted dimensions of treatment burden such
as medication or costs, for example, [68, 69]. Some authors
calculated treatment burden with respect to the number of
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treatment episodes or in terms of level of treatment inten-
sity [46, 51]. Others explored how treatment burden influ-
enced treatment decisions [18, 70, 80] and developed an
associated measure [80]. This measure, Willingness to
Accept Life-Sustaining Treatment (WALT) was also utilized
by Janssen et al. [44] for Dutch patients with two of the
three conditions explored by Fried et al. [80]: chronic ob-
structive pulmonary disease and chronic heart failure.
Other authors stated that they measured treatment burden
but provided minimal or no detail on the actual measure-
ment process or sub-scales used [20, 44, 48, 55, 56, 78].
Readers would therefore need to search beyond the paper
to identify what dimensions of treatment burden were in-
cluded. There were also some papers that referred to treat-
ment burden but focused predominantly on experiences of
living with a chronic condition, rather than treatment bur-
den per se [73, 74], or alternatively, focused on both, i.e. the
burden of symptoms and treatment, as seen in Liu et al.
[47]. Finally, there were several papers that focused on un-
derstanding treatment experiences and included several
broad or specific questions on treatment burden [20, 64].
Robertson et al. [63] was unique in that it surveyed regular
medication users and the impact of financial and medica-
tion burden (in addition to other variables) on choosing to
take a new medication.
The most common dimension of treatment burden ex-
amined in Group 2 was related to medication use, generally
around diabetes management (e.g., blood glucose monitor-
ing), e.g., [19, 38, 39, 49, 79], and other chronic diseases,
such as asthma [71], attention deficit hyperactivity disorder
[69] and stroke [23]. Based on the limited information on
survey development in many studies, it appeared that medi-
cation burden was measured by asking participants ques-
tions related to their experiences of taking medication,
including, but not limited to, side effects, inconvenience,
e.g. from carrying, storing, and administering medication,
and impact on lifestyle, e.g. diabetic medication and effect
on meal times, exercise and/or diet [19, 48, 79]. Alterna-
tively, one broad treatment burden question was included
by Hanke et al. [43], who asked participants with actinic
keratosis how much of a problem had the treatment been,
‘for example by making your home messy, or by taking up
time?’ Some studies identified the total number of thera-
peutic drug classes or medications a person was taking, i.e.
polypharmacy, as a sign of treatment burden [23, 49, 58–
60]. Yet, there was acknowledgement by Gallacher et al.
[23] that medication use represents only one dimension of
treatment burden; other considerations include financial
burden and healthcare access [23]. Five papers investigated
the relationship between treatment burden (alongside a
range of other variables) on medication adherence [50, 55,
61, 72, 75]. For example, a question asked to adolescents
with cystic fibrosis was ‘are there other things, besides the
time involved, that make it difficult to do your therapies or
take your medicines?’ [72]. Similarly, Hock et al. [61] asked
the following question: ‘Treatments have been burdensome
on my family's resources, e.g. money, time, energies.’
Following medication, there was an emphasis on finan-
cial burden or the cost of treatment for participants and
their families. For example, Colombo et al. [40] exam-
ined the medical costs (i.e. hospitalizations, outpatient
medical interventions, medication, devices and dietetic
products) associated with treating cystic fibrosis in Italy.
Additionally, Kent et al. [45] investigated, via three ques-
tions, whether cancer survivors who experienced finan-
cial problems were likely to forgo or delay medical care,
such as counselling, dental care, checkups, or prescrip-
tion medication. Qualitative interviews with lung trans-
plant recipients and health professionals identified
treatment burden as a novel health-related quality of life
dimension, including financial costs [76]. Among the pa-
pers that focused on financial burden, there was also at-
tention on the cost of treatment upon the family unit, in
addition to the patient [45]. Thus, it was evident that the
cost of treatment, particularly medication, was a well-
established concern for participants.
Within Group 2, there was significant interest in under-
standing the burden of treatment for cystic fibrosis, for chil-
dren, adolescents, adults, and parents [36, 40, 52–54, 57,
65, 75]. A total of 12 Group 2 papers focused on cystic fi-
brosis, although the study by Ziaian et al. [68] also included
participants with asthma and diabetes. The general focus of
these studies was on quality of life; treatment burden was
measured as part of living with cystic fibrosis, generally via
two or three items. However, detailed information on this
was missing from many papers. Most of these papers
simply indicated that health related quality of life for cystic
fibrosis was measured, which included physical functioning,
treatment burden and respiratory symptoms. Nevertheless,
the large number of papers that focused on cystic fibrosis
confirmed that this particular chronic condition is associ-
ated with high treatment burden.
There was also a focus on investigating the burden of treat-
ment on specific treatment interventions. Most of these pa-
pers measured treatment burden via one or two simple
questions, which asked about general treatment experiences.
These measures were not grounded in theory and lacked a
clear focus on treatment burden. Rather, they were generally
focused on the impact of a particular treatment intervention.
For example, for two Randomized Control Trial (RCT) pa-
tient groups on varying medication for proliferative lupus
nephritis, Grootscholt et al. [42] measured the associated
burden of treatment via a 5-point Likert scale and used
open-ended questions, for example, exploring which aspect
of treatment was perceived as most burdensome. Baylor et al.
[22] investigated treatment burden for spasmodic dysphonia
by asking participants how Botox treatment affected their
ability to do things they wanted to do. Levinson et al. [77]
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asked past ICU patients whether they thought their treat-
ment was worthwhile. Finally, Drabe et al. [66] asked partici-
pants with thyroid cancer, and their partners, about how they
experienced surgery and what they felt about the radioactive
iodine treatment and associated treatment isolation.
Group 3 - indirect measures
There were a total of 35 papers in this group; 23 of these
were quantitative [81–103], 10 were qualitative [104–113],
and two mixed-methods [114, 115].
Although Group 3 papers did not specifically mention
treatment burden or burden of treatment, careful analysis
suggested that they measured the dimensions of burden put
forward by Sav et al’s [8] review, such as medication, time/
travel and cost of treatment. Rather than concentrating on
treatment burden, these papers generally focused on treat-
ment experiences and included arbitrary questions that
measured some dimensions of treatment burden. For ex-
ample, Broom et al. [85] used a questionnaire with ques-
tions relating to bone treatment convenience, e.g. did
treatment for bone disease take up family time and were
participants concerned about associated side effects. Simi-
larly, Passik [97] asked participants undergoing cancer treat-
ment about common treatment side effects, such as weight
loss, constipation, nausea, pain, or vomiting. DeSmedt et al.
[88] asked heart failure patients about adverse drug events,
without specifically discussing treatment burden. Eiser and
Upton [89] aimed to provide estimates of the cost of caring
for a child with cancer, without specifically discussing how
the cost of treatment could be a critical dimension of treat-
ment burden. In contrast to the afore-mentioned studies,
Blome et al. [84] assessed the importance of treatment goals
for people with moderate to severe psoriasis. Participants
acknowledged the importance of low treatment burden with
respect to time/travel and costs. A mixed-method study by
Tijerina [115] explored the experiences of Mexican-
American women receiving dialysis treatment, and identi-
fied a loss of identity from changes in their body image, loss
of independence, freedom and ability to fulfil social roles.
Furthermore, women who expressed concerns about body
image were more likely to be non-adherent to treatment
(Tijerina 2006).
As can be seen from the examples provided, a large
number of studies (n = 22) focused on medication re-
lated factors, which is a commonly accepted dimension
of treatment burden. Most of these studies aimed to
understand the experiences of participants whilst using
prescribed medication or treatments, such as dialysis or
surgical procedures, and talked about issues, such as
medication side effects, cost, inconvenience or changes
in treatment, and feelings whilst taking medications.
There were also instances where medication burden or
polypharmacy was the general focus of the study and
was calculated with the number of medications a person
was taking, for example, using more than five medica-
tions was classified as burdensome [60, 92, 93], or by the
number of medications dispensed or filled [82]. This, as
noted by the authors, assumed that patients actually used
what was supplied to them. In addition to medication, there
was also a focus on cost of treatment [89, 102, 103] and
time and travel burden [81, 86, 95, 96]. For example, United
States (US) families at a higher risk of experiencing time
burden from caring for children with chronic conditions in-
cluded those from a lower income and educational back-
ground, were culturally diverse, lived in a rural location and
had public health insurance [95]. Furthermore, the more se-
vere the child’s chronic condition, the higher the risk of
time burden. The issue of time and financial burden was
also emphasised by caregivers of children with chronic con-
ditions in a Canadian study [102]. Although these papers
appeared similar to those in Group 2, the fundamental dif-
ference was that these papers did not specifically mention
treatment burden in the text, and focused on investigating
medication or treatment-related experiences. Alternatively,
Group 2 papers mentioned the term ‘treatment burden’
and investigated medication related issues as a way of un-
derstanding the level of treatment burden.
Some of the studies focused on understanding the illness
or treatment journey among participants with chronic con-
ditions, particularly cancer [98, 108–111, 114]. For example,
Shadid et al... [110] investigated the experiences and barriers
of Aboriginal people in accessing cancer services and treat-
ment. The authors found that transport, accommodation
and travel expenses were a concerning issue for this specific
population whilst undergoing cancer treatment. Similarly,
Salter et al. [109] explored the perceptions of dialysis and
kidney transplant among African American adults undergo-
ing haemodialysis. Although Salter et al’s [109] paper did
not specifically focus on treatment burden per se, the re-
sponses of participants during the focus group interviews
clearly indicated episodes of treatment burden, with one
participant admitting: “I used to feel like Superman. I’m un-
healthy. This dialysis thing is like kryptonite. It sucked every-
thing out of me.” Also, Clark et al. [114] explored treatment
decisions by prostate cancer patients, which could be related
to treatment burden, e.g. regretting treatment choice. Staj-
duhar et al. [111] wanted to understand the experiences and
educational needs of Canadian adults receiving iodine ther-
apy for thyroid cancer. In-depth responses to the question
‘tell me about your experiences when you were a patient on
our unit,’ generated treatment burden-related responses,
such as feeling socially and physically isolated during treat-
ment. In a qualitative study, Bower et al. [104] interviewed
28 participants with various co-morbidities (including can-
cer) to identify how they perceived, and responded to, their
condition/s, i.e. illness representations. The authors identi-
fied concerns related to medication burden, such as addic-
tion to pain killers and quantity of medication prescribed.
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Finally, in some papers, there was also a focus on reduc-
tion strategies that participants employed to minimize
treatment burden. Burcu et al. [87] asked participants if
they actively implemented strategies to reduce medication
costs. For example had participants taken smaller doses,
or skipped doses, of a medication to make it last longer,
decided not to fill or refill a prescription because it was
too expensive, or spent less money on food, heat or other
basic needs to be able to afford medication, etc. Bower et
al... [104] found that many patients took multiple medica-
tions for co-morbidity and when they prioritized a chronic
condition, they also prioritized the medication used to
treat that condition.
Discussion
This scoping review reveals a significant variation in how the
treatment burden experienced by those with chronic disease,
has been operationalized and measured. These variations re-
flect the evolving and developing nature of the treatment
burden literature, as well as the diversity of chronic condi-
tions experienced. Indeed, research on treatment burden has
significantly increased since May et al’s (2009) seminal work.
This has led to the development of various measures to as-
sess and understand the level of treatment burden experi-
enced by those with chronic disease. However, our review
indicates that despite this growing research interest and sub-
stantial progress, research gaps remain.
Firstly, our review highlights the dominance of quantita-
tive based papers to understand and measure treatment
burden; 64 of the 101 studies in this review were quantita-
tive. Despite the widely known strengths of quantitative re-
search, the limited use of qualitative methods limits our
ability to understand, in-depth, treatment burden experi-
ences among specific populations. For example, a qualita-
tive approach may be preferred over a quantitative method,
when there is a need to explore and understand, in-depth,
how non-traditional and minority populations experience
treatment burden. We believe that Eton et al’s [25] and Kar-
amanidou et al’s [28] work provide a useful starting point
for a focus on qualitative research. In their qualitative paper,
Eton et al. [25] provided an 11 question interview schedule,
which asks participants about their health condition/s and
how they care for them, the impact of treatments and med-
ical self-care on their daily life, difficulties accomplishing
self-care, relationships with health professionals, financial
problems and the factors that may alleviate treatment and
self-care burden [26]. Additionally, Karamanidou et al’s [28]
paper, which uses IPA, includes a valuable interview sched-
ule, which can be easily amended to reflect the type of
chronic condition under investigation. Researchers have
much to gain from using exploratory qualitative research
methods to further conceptualize treatment burden and
understand how it occurs, before assessing levels of treat-
ment burden among large populations. This is not to say
that qualitative research should be conducted at the
expense of quantitative research but rather, both should be
utilized to obtain a more in-depth and comprehensive ex-
planation. Therefore, further mixed-methods research
would be highly valuable in this area. Additionally, the
question remains as to whether all domains of treatment
burden are equally important. While many studies included
in this review focused on medication burden, further stud-
ies may be needed to identify if this is really the most im-
portant dimension of treatment burden, and whether this
changes depending on study population.
Secondly, despite the plethora of quantitative based re-
search, it is clear that creating a measurement question-
naire/survey to assess levels of treatment burden is still in
its infancy phase. Although there has been increasing inter-
est in treatment burden, our review indicates that only a
handful of studies focus solely on the concept of treatment
burden and offer systematic measures [6, 9, 21, 25, 26, 28,
30]. The primary focus for most Group 2 and 3 papers was
on understanding the level of treatment burden as a com-
ponent of overall treatment experience or the burden of
living with a chronic condition. While this is valuable, most
studies make little reference to treatment burden and sim-
ply measure it via one or two items or as an aggregated fig-
ure. However, previous research has shown [8] that
treatment burden is a subjective concept and one person’s
response to a particular treatment intervention may be very
different to another person undergoing the same treatment.
Research has suggested that individual capacity issues relat-
ing to the individual and their wider support networks will
influence response and ability to cope with any given level
of treatment burden [116]. Hence, it is likely to be inad-
equate to simply measure treatment burden by asking par-
ticipants if they take more than five prescription
medications, as seen in this review.
Additionally, it seems unlikely that asking participants to
estimate their level of treatment burden via two or three
questions will fully capture the multi-dimensional nature of
treatment burden. At best, two or three questions on treat-
ment burden would only be sufficient to aid understanding
of one dimension of this concept, such as medication use.
We recommend looking at the psychometric literature for
guidance about the development and validation of ques-
tionnaires. This body of literature can offer guidance
around the number, length, and wording of questions, data
collection and pilot testing, validation and evaluation, reli-
ability and validity. In the meantime, Eton et al’s [26, 30] re-
cent PETS measure, along with Tran et al’s [9, 21] TBQ are
promising and can be a valuable starting point in this area.
However, we do acknowledge that trying to understand
levels of treatment burden via lengthy surveys or long lists
of questions may not always be possible because of time
constraints, particularly in a clinical setting. Hence, it would
be valuable to develop a short measure to identify levels of
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treatment burden in a clinical setting and implement strat-
egies to alleviate its impact. This will not only be valuable in
a clinical setting but also could accompany other measures
focusing on high burden conditions, such as cystic fibrosis. A
short measure of treatment burden could easily complement
other measures where the focus is on understanding quality
of life or the experiences of living with a particular chronic
condition. However, we do caution against using short mea-
sures for scientific purposes, where the intent would be on
understanding the dimensionality of treatment burden.
Thirdly, our scoping review highlights a lack of longi-
tudinal designs to understand and measure treatment
burden. Given that levels of treatment burden experi-
enced by a person can change over time in response to
disease severity and control and the development of
other chronic conditions [8], the limited number of lon-
gitudinal studies could be viewed as problematic. Meas-
uring treatment burden via cross-sectional study
designs, as it has been done, impedes our ability to fully
understand the dynamic nature of treatment burden.
Fourthly, our review has also confirmed the scant evi-
dence of treatment burden in developing countries and
culturally different populations. The overwhelming major-
ity of studies have been conducted among Anglo-Saxon
populations in affluent, high-income countries such as the
United States, United Kingdom, Canada, Australia and
France. Thus, there is limited knowledge about the experi-
ences of people in different health contexts and among
specific racial and cultural populations. The lack of re-
search among such populations is problematic because
understandings of key concepts, such as death, illness,
health and treatment can be very different in non-
traditional societies. For example, is it not uncommon for
people in certain cultures in some countries (e.g. Ghana in
Africa) to perceive illness as a form of retribution from
their gods and not a condition which can be treated med-
ically [117]. We caution researchers to be vigilant about
the applicability of measures developed in Western soci-
eties to understand treatment burden in non-traditional
societies and populations. Although this is important for
testing the robustness of the measures and original con-
clusions in Western societies, it is unwise to assume that
they can be uncritically applied elsewhere. Instead, what
may be more suitable are qualitative exploratory research
methods, such as in-depth interviews to conceptualize the
meaning and measure levels of treatment burden for
people from diverse cultural backgrounds.
Finally, we think that a fundamental theme that is missing
from current measures of treatment burden is identity. Des-
pite the recognition of the impact of treatment workload on
everyday activities, how treatment burden influences a per-
son’s identity is limited (Demain et al. [10] and Tijerina
[115]). There is also scant evidence on whether there is gen-
der, age or cultural differences in treatment burden. Identity,
which can be highly associated with gender, may offer a
missing link to explaining the subjective and dynamic nature
of treatment burden. Sav et al’s [3] recent paper, suggested
that younger adults with chronic condition/s experience
greater levels of treatment burden, compared to older adults.
Although the authors argue that there may be several expla-
nations to this finding, one possible reason could be related
to the issue of identity. More specifically, elderly adults may
be more likely to accept treatment burden as a necessary evil
brought on by old age and living with multimorbidity. This
group may become accustomed to the treatment workload
or have more time when they retire. In contrast, treatment
burden may less socially sanctioned in younger adults, who
are expected to foster a healthy, productive, and active iden-
tity. Considering identity in treatment burden may help un-
ravel many of the nuances of this concept and further
attention is warranted in this area. Importantly, this suggests
future research needs to examine how the concept of treat-
ment burden may differ depending on variables such as age,
gender, or cultural setting.
To our knowledge, this is the most comprehensive re-
view of the treatment burden literature to date. Yet, it has
a several limitations that must be acknowledged. It is pos-
sible that we may have missed papers that measure this
concept. For example, this review was restricted to English
language only papers, and hence, may have missed key pa-
pers measuring treatment burden in non-English speaking
samples. However, there is growing evidence that this is
unlikely to be a major problem [118]. The paucity of stud-
ies reporting the issue of treatment burden in low income
countries could be considered a further limitation. Quality
appraisal of the papers was not undertaken, however this
aligns with the intention of a scoping review [14] which
aimed to be comprehensive in providing a narrative and
descriptive account of the current state of evidence on
measuring treatment burden.
Conclusions
Although research on treatment burden is growing rapidly,
there is still much ground to cover and work to be done.
Outstanding research issues that need addressed include a
greater qualitative focus, more research with non-traditional
populations in developing countries, a greater emphasis on
longitudinal studies and the consideration of the potential
effects of “identity” on treatment burden.
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